Are we HER-ting for innovation in neoadjuvant breast cancer trial design? - Wikidata - wikimedia - TriplyDB

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

http://www.wikidata.org/entity/Q37205521

about

Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

P2860

Q34408090-F6669539-AF62-4FA7-82EB-0F25A0E3B723 Q48222174-2BFC9D92-3A03-4B32-B365-AB162EEE0FE1 Q54506148-0B964F96-6A9F-4F35-A5F0-F21EBB1C2788

P2860

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

http://www.wikidata.org/entity/Q37205521

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

@en

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

@nl

type

label

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

@en

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

@nl

prefLabel

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

@en

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

@nl

P1433

Q37205521-8436F0D5-C281-4101-BBEC-C112FDDD550E

P1476

Q37205521-F8C0E559-6D86-4F9E-BCCE-D8EA5EF67C52

P2093

Q37205521-2CFEC12C-58D5-4A58-BA8D-257EB0C6557E

Q37205521-D7CFF7A6-DC92-44A1-BBAB-F656FEDB7C38

P2860

Q37205521-038DDBB5-E58B-4F8D-9E94-4258825C8913

Q37205521-1711678B-6F4C-42BE-96C6-F0239CE6CF9B

Q37205521-1750D727-E74E-4DE2-A9A1-277A3496A902

Q37205521-17C68F60-97D9-4937-B799-2584561F09C5

Q37205521-1CBE3685-F5DC-4067-8A0E-B43D7019E459

Q37205521-210FDBFC-E1F9-44A0-8D61-B105815662E6

Q37205521-24E8920B-FB9A-4E02-848A-35B9898CC70A

Q37205521-2E9E8606-4E27-4A0A-AB0C-7ED3D3BF3B5F

Q37205521-334D05C0-E332-4E27-AA9C-43D0875BDF24

Q37205521-45649DF7-B644-4B0F-BE37-250D8E1FDACD

P2888

Q37205521-8A55AB41-1204-47D5-8F5E-B6FFCB70FD1C

P304

Q37205521-3A0B13F3-42DE-4FB2-8348-084B338EBD32

P31

Q37205521-3E878EB8-EFF4-4ADF-A38B-DB2BB0EAD209

Q37205521-9F187C26-2086-48AA-828C-BC11FA5AB971

P356

Q37205521-FC39799C-466E-45E2-B1A9-998884AB1A49

P433

Q37205521-D43BC36A-CE8F-4499-BF15-DAD6C1B66748

P478

Q37205521-A531F6C3-F0E8-4966-A3E1-00067634C2A7

P50

Q37205521-18A203F4-BA43-42E2-9CE9-87BBD519A37C

Q37205521-4F0BC714-5106-4B38-99D4-05EED500EE26

Q37205521-7A2DCA97-BBB6-4BAA-BC86-168DA5260ED5

P577

Q37205521-C535EA44-26A5-4103-998D-9025320E0F77

P5875

Q37205521-D4333B12-05C2-454B-BE6D-A38D9C126A13

P6179

Q37205521-BCC1C07F-56DC-42CE-AE66-8B457F04F037

P698

Q37205521-20C1C6C1-4F7D-4951-BDE2-6E2F10F87174

P921

Q37205521-150E479B-273C-472D-B6AC-C584BA708840

Q37205521-25C1B509-116B-48C8-819A-34AD77F8E100

Q37205521-B2B70010-1008-4BF4-A3A9-3AE05002155C

P932

Q37205521-CF4C3176-C7C7-4EAF-B7A9-67F3C286810E

P356

P1433

Breast Cancer Research

P1476

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

@en

P2093

Martine Piccart

http://www.w3.org/2001/XMLSchema#string

Natasa Snoj

http://www.w3.org/2001/XMLSchema#string

P2860

Imaging in breast cancer: diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

P2888

P304

201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2209

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Evandro de Azambuja

Philippe L. Bedard

P577

2009-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24009976

http://www.w3.org/2001/XMLSchema#string

P6179

1028729591

http://www.w3.org/2001/XMLSchema#string

P698

19216727

http://www.w3.org/2001/XMLSchema#string

P921

breast neoplasm

biomedical investigative technique

P932

2687702

http://www.w3.org/2001/XMLSchema#string